New Company Sloning BioTechnology GmbH Launches With The Production Of Synthetic Genes Using Slonomics Technology

PUCHHEIM, Germany & MUNICH, Germany--(BUSINESS WIRE)--July 19, 2006--Sloning Biotechnology announces its market entry. As of July, the company produces synthetic genes using the novel Slonomics(TM) technology.

Slonomics(TM) utilises a library of universal double-stranded DNA building blocks. In a highly standardised biochemical process, the desired gene is assembled by industrial robotic machines. In light of the quality of the raw materials and the highly standardised and automated process, Slonomics(TM) is considered superior to other gene synthesis techniques. The customer, in particular, benefits from this: estimated delivery times are reliable, and even difficult-to-synthesise genes can be constructed without difficulty or delay. With this technology, previous restrictions on sequence design are eliminated.

"The challenging research and development phase of the last several years has paid off. It is amazing to see how an idea can become a reality. Our Slonomics(TM) technology is the logical consequence of a growing need for synthetically constructed genes. We are sure that this technology will increase the size of the market for such gene products, and that it will soon replace older gene synthesis methods," stated Dr. Heinz Schwer, the company CEO.

Dr. Thomas Waldmann, the business developer at Sloning, commented that "Slonomics(TM) fills a technological gap between automated genome sequencing and proteomics. In addition, this technology allows for the development of completely new applications in the field of enzyme optimisation, which is also an important contribution to white biotechnology."

Sloning Biotechnology hopes to position itself as the innovator and technological leader in the market. Not only the competitive advantages, but also the enabling potential of the Slonomics(TM) technology will be emphasised.

Sloning Biotechnology is a biotech company that operates in the realm of genomics. The company is located in Puchheim (just west of Munich) and currently employs 20 staff members. Following successful development of the fully automated Slonomics(TM) process, the company intends to take on a leading role in the field of synthetic gene production. www.sloning.com

Contact: Sloning Biotechnology Dr Thomas Waldmann, +49 89 80 90 950 t.waldmann@sloning.de info@sloning.com

Source: Sloning Biotechnology

Back to news